Pluristyx and Solesis Launch First-of-its-Kind PluriForm-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection
New ready-to-use kit combines Pluristyx’s high-quality pluripotent cells and mRNA technology with…
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
February 05, 2026 07:01 ET | Source: BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE…
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026 07:00 ET | Source: Dianthus Therapeutics, Inc. NEW YORK…
Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast…
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its…
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
February 04, 2026 09:35 ET | Source: Adial Pharmaceuticals, Inc GLEN ALLEN,…
Berry Street Named to 2026 New York Digital Health 100 List
Digital Health New York recognizes nutrition therapy platform’s innovative approach to evidence-based…
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader…
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
February 03, 2026 13:06 ET | Source: Restem Initiation of the IIMPACT…
